Effects of nebivolol on biomarkers in elderly patients with
heart failure

J 2014

Effects of nebivolol on biomarkers in elderly patients with heart failure

TANEJA, Anil K., David GAZE, Andrew J.S. COATS, Dan DUMITRASCU, Lenka ŠPINAROVÁ et. al.

Základní údaje

Originální název

Effects of nebivolol on biomarkers in elderly patients with heart failure

Autoři

TANEJA, Anil K. (826 Velká Británie a Severní Irsko), David GAZE (826 Velká Británie a Severní Irsko), Andrew J.S. COATS (36 Austrálie), Dan DUMITRASCU (642 Rumunsko), Lenka ŠPINAROVÁ (203 Česká republika, garant, domácí), Paul COLLINSON (826 Velká Británie a Severní Irsko), Michael ROUGHTON (756 Švýcarsko) a Marcus D. FLATHER (826 Velká Británie a Severní Irsko)

Vydání

International Journal of Cardiology, Ireland, ELSEVIER IRELAND LTD, 2014, 0167-5273

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.036

Kód RIV

RIV/00216224:14110/14:00076540

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.ijcard.2014.05.018

UT WoS

000340249400013

Klíčová slova anglicky

Beta blockers in heart failure; Neurohormones; SENIORS substudy; Nebivolol; NT-Pro BNP and beta blockers

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 9. 2014 13:55, Soňa Böhmová

Anotace

V originále

Background: Heart failure activates neurohormones, and elevated levels of brain natriuretic peptide (BNP) are associated with adverse outcomes. The SENIORS trial showed that nebivolol, a highly selective beta-1 antagonist with vasodilating properties, reduced the composite outcome of all cause mortality or cardiovascular hospital admissions in older patients with heart failure. We explored the effects of nebivolol on a range of neurohormones, cytokines and markers of nitric oxide activity in heart failure. Methods: In a subset of patients in SENIORS we measured N-terminal pro-brain natriuretic peptide (NT-BNP), pro atrial natriuretic peptide (Pro-ANP), endothelin-1 (ET-1), peripheral norepinephrine (PNE), soluble Fas (sFas), soluble Fas-ligand (sFas-L), tumour necrosis factor-alpha (TNF-alpha), serum uric acid (SUA), symmetrical dimethyl arginine (SDMA), arginine, citrulline and asymmetrical dimethyl arginine (ADMA) at baseline (before study drug), at 6 months and 12 months in a prespecified substudy. Results: One hundred and six patients were enrolled and 75 had a baseline and at least one follow-up sample. There were no significant differences in neurohormone cytokines or nitric oxide markers measured between the two groups at six or twelve months. NT-ProBNP showed a numerical increase in the nebivolol group compared to placebo (P = 0.08) and sFas showed a numerical increase in patients on placebo (P = 0.08). Mean baseline LVEF was 35% in both groups and at 12 months was 43% on nebivolol group and 34% on placebo group (P = 0.01). Conclusion: There were trends but no clear changes associated with nebivolol in neurohormones, cytokines or markers of nitric oxide activity in this study of elderly patients with heart failure. Further studies are needed to understand the mechanistic effects of beta blockers on biomarkers in heart failure.

Citovat

TANEJA, Anil K., David GAZE, Andrew J.S. COATS, Dan DUMITRASCU, Lenka ŠPINAROVÁ, Paul COLLINSON, Michael ROUGHTON a Marcus D. FLATHER. Effects of nebivolol on biomarkers in elderly patients with heart failure. International Journal of Cardiology. Ireland: ELSEVIER IRELAND LTD, 2014, roč. 175, č. 2, s. 253-260. ISSN 0167-5273. Dostupné z: https://dx.doi.org/10.1016/j.ijcard.2014.05.018.

@article{1198909,
   author = {Taneja, Anil K. and Gaze, David and Coats, Andrew J.S. and Dumitrascu, Dan and Špinarová, Lenka and Collinson, Paul and Roughton, Michael and Flather, Marcus D.},
   article_location = {Ireland},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.ijcard.2014.05.018},
   keywords = {Beta blockers in heart failure; Neurohormones; SENIORS substudy; Nebivolol; NT-Pro BNP and beta blockers},
   language = {eng},
   issn = {0167-5273},
   journal = {International Journal of Cardiology},
   title = {Effects of nebivolol on biomarkers in elderly patients with heart failure},
   volume = {175},
   year = {2014}
}

TY  - JOUR
ID  - 1198909
AU  - Taneja, Anil K. - Gaze, David - Coats, Andrew J.S. - Dumitrascu, Dan - Špinarová, Lenka - Collinson, Paul - Roughton, Michael - Flather, Marcus D.
PY  - 2014
TI  - Effects of nebivolol on biomarkers in elderly patients with heart failure
JF  - International Journal of Cardiology
VL  - 175
IS  - 2
SP  - 253-260
EP  - 253-260
PB  - ELSEVIER IRELAND LTD
SN  - 01675273
KW  - Beta blockers in heart failure
KW  - Neurohormones
KW  - SENIORS substudy
KW  - Nebivolol
KW  - NT-Pro BNP and beta blockers
N2  - Background: Heart failure activates neurohormones, and elevated levels of brain natriuretic peptide (BNP) are associated with adverse outcomes. The SENIORS trial showed that nebivolol, a highly selective beta-1 antagonist with vasodilating properties, reduced the composite outcome of all cause mortality or cardiovascular hospital admissions in older patients with heart failure. We explored the effects of nebivolol on a range of neurohormones, cytokines and markers of nitric oxide activity in heart failure. Methods: In a subset of patients in SENIORS we measured N-terminal pro-brain natriuretic peptide (NT-BNP), pro atrial natriuretic peptide (Pro-ANP), endothelin-1 (ET-1), peripheral norepinephrine (PNE), soluble Fas (sFas), soluble Fas-ligand (sFas-L), tumour necrosis factor-alpha (TNF-alpha), serum uric acid (SUA), symmetrical dimethyl arginine (SDMA), arginine, citrulline and asymmetrical dimethyl arginine (ADMA) at baseline (before study drug), at 6 months and 12 months in a prespecified substudy. Results: One hundred and six patients were enrolled and 75 had a baseline and at least one follow-up sample. There were no significant differences in neurohormone cytokines or nitric oxide markers measured between the two groups at six or twelve months. NT-ProBNP showed a numerical increase in the nebivolol group compared to placebo (P = 0.08) and sFas showed a numerical increase in patients on placebo (P = 0.08). Mean baseline LVEF was 35% in both groups and at 12 months was 43% on nebivolol group and 34% on placebo group (P = 0.01). Conclusion: There were trends but no clear changes associated with nebivolol in neurohormones, cytokines or markers of nitric oxide activity in this study of elderly patients with heart failure. Further studies are needed to understand the mechanistic effects of beta blockers on biomarkers in heart failure.
ER  -

TANEJA, Anil K., David GAZE, Andrew J.S. COATS, Dan DUMITRASCU, Lenka ŠPINAROVÁ, Paul COLLINSON, Michael ROUGHTON a Marcus D. FLATHER. Effects of nebivolol on biomarkers in elderly patients with heart failure. \textit{International Journal of Cardiology}. Ireland: ELSEVIER IRELAND LTD, 2014, roč.~175, č.~2, s.~253-260. ISSN~0167-5273. Dostupné z: https://dx.doi.org/10.1016/j.ijcard.2014.05.018.

Podrobný výpis o publikaci